HCV

Despite encouraging preclinical safety and efficacy data for its RNAi-based hepatitis C treatment, Somagenics has decided to step back from its previous plan to push the agent into phase I testing this year as it waits to see how more advanced small-molecule therapies fare in lat

The primary motivation for PerkinElmer's acquisition of Chinese infectious disease diagnostic firm Shanghai Haoyuan Biotech, announced this week, is to provide the Waltham, Mass.-based firm entrée into the nucleic acid-based blood screening market, company executives said this we

Two years after the US Patent and Trademark Office reinstated its core patent, Australia's Benitec Biopharma has once again set its sights on finding licensees for its expressed RNAi intellectual property.

The Association for Molecular Pathology's annual meeting, held last week in Long Beach, Calif., focused strongly on next-generation sequencing and its implementation in the clinic, especially for diagnosing, monitoring, and tailoring treatments for cancer.

Australian expressed RNAi drug developer Benitec this week provided an update to its pipeline, disclosing that it once again expects to have a candidate in phase I testing next year following its recent acquisition of Tacere Therapeutics.

Just six years after a troubled Benitec Biopharma licensed its expressed RNAi hepatitis C drug program to Tacere Therapeutics, a startup founded by former Benitec executives, the two companies have agreed to merge.

Benitec announced this week that it has received a Chinese patent covering the use of its expressed RNAi constructs against hepatitis C.

Two independent research groups this week reported in The Journal of Clinical Investigation on the role of microRNA-122 in the liver, showing that the non-coding RNA is critical for fat and cholesterol metabolism in the organ and that it may play an important role in tum

Tacere Therapeutics is prepared to file an investigational new drug application for an expressed RNAi treatment for hepatitis C, but is looking to partner the program before doing so after previous collaborator Pfizer pulled back on its in-house RNAi drug efforts, according to Be